Bioptic EBIT/Varat

Mitä Bioptic tekee? Bioptic Inc, listed on the Taiwan Stock Exchange under ticker 6850.TWO with ISIN TW0006850001, is headquartered in Taipei, Taiwan. The company went public via an IPO on November 10, 2021. Bioptic Inc focuses on the research, development, production, and sale of capillary electrophoresis apparatus and related consumables and nucleic acid detection reagents. Its product portfolio includes testing instruments, cassettes, and reagents. The company's detection equipment features the Qsep100 series, Qsep1 series, and Qsep400 series of capillary electrophoresis instruments designed for the separation and detection of biomolecules. Its cartridge offerings include the S1, S2, S3, and F3 series for DNA fragment detection, R1 and NR1 series for RNA detection, P2 series for protein detection, and quantitative detection Q series. The reagents provided by the company encompass polymerase chain reaction reagents, veterinary medicine-related reagents, human gene detection-related reagents, and food-related reagents. Bioptic Inc primarily serves markets in China, Hong Kong, Taiwan, and other regions. The company's operations are centered around the development and commercialization of specialized equipment and reagents for biomolecular analysis, targeting applications in research, diagnostics, and related fields. The firm's website is https://www.bioptic.com.tw/. Bioptic on yksi Eurpooliin suosituimmista yhtiöistä.